Cargando…

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Detalles Bibliográficos
Autores principales:	Birring, Surinder S., Dicpinigaitis, Peter V., Smith, Jaclyn A., Morice, Alyn H., McGarvey, Lorcan P., Pavord, Ian D., Nguyen, Allison Martin, Schelfhout, Jonathan, Li, Qing, Iskold, Beata, Green, Stuart A., Philip, George, Muccino, David R., La Rosa, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263136/ https://www.ncbi.nlm.nih.gov/pubmed/36996347 http://dx.doi.org/10.1164/rccm.202211-2128LE

Ejemplares similares

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021)

Treating acute cough: wet versus dry – have we got the paradigm wrong?
por: Morice, Alyn H., et al.
Publicado: (2015)

Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough
por: Nguyen, Allison Martin, et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2022)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Reply to Weinberger
por: Birring, Surinder S., et al.
Publicado: (2023)

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough
por: Mazzone, Stuart B., et al.
Publicado: (2020)

From bench to bedside: The role of cough hypersensitivity in chronic cough
por: Drake, Matthew G., et al.
Publicado: (2023)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
por: Morice, Alyn, et al.
Publicado: (2021)

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019)

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
por: Friedrich, Christian, et al.
Publicado: (2023)

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
por: Dicpinigaitis, Peter V., et al.
Publicado: (2023)

Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough
por: Schelfhout, Jonathan, et al.
Publicado: (2022)

Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Cough hypersensitivity and chronic cough
por: Chung, Kian Fan, et al.
Publicado: (2022)

Validation of a visual analog scale for assessing cough severity in patients with chronic cough
por: Martin Nguyen, Allison, et al.
Publicado: (2021)

Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel
por: Kum, Elena, et al.
Publicado: (2022)

Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough
por: Ludbrook, Valerie J., et al.
Publicado: (2021)

An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma
por: Holmes, Joshua, et al.
Publicado: (2022)

New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study
por: Zhang, Mengru, et al.
Publicado: (2023)

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Impact of refractory and unexplained chronic cough on disease burden: a qualitative study
por: Ueda, Naoya, et al.
Publicado: (2022)

Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study
por: Song, Woo-Jung, et al.
Publicado: (2023)

Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses
por: Song, Woo-Jung, et al.
Publicado: (2021)

Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis
por: Zheng, Ziwen, et al.
Publicado: (2023)

The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute)
por: Yousaf, Nadia, et al.
Publicado: (2011)

Recent progress in the management of chronic cough
por: Song, Woo-Jung, et al.
Publicado: (2020)

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)

Combating cough
por: Morice, Alyn H
Publicado: (2016)

ATP, an attractive target for the treatment of refractory chronic cough
por: Zhang, Mengru, et al.
Publicado: (2022)

COUGH: consolidating a mature field for the next 5 years
por: Chung, Kian Fan, et al.
Publicado: (2011)

An update and systematic review on drug therapies for the treatment of refractory chronic cough
por: Ryan, Nicole M., et al.
Publicado: (2018)

Chronic cough hypersensitivity syndrome
por: Morice, Alyn H
Publicado: (2013)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

Anatomy and Neurophysiology of Cough: CHEST Guideline and Expert Panel Report
por: Canning, Brendan J., et al.
Publicado: (2014)

Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature
por: Holmes, Joshua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7qoehc406p10h1n2gcdejami8e